persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВАpersmed-11Research ArticleОБЗОРЫREVIEWERSАнтимикробные пептиды врожденного иммунитета как прототипы новых средств борьбы с антибиотикорезистентными бактериямиAntimicrobial peptides of innate immunity as prototypes of new agents to fight antibiotic-resistant bacteriaШамоваО. В.ShamovaO. V.

Шамова Ольга Валерьевна, д.б.н., чл.-корр. РАН, заместитель директора по научной работе, заведующий отделом общей патологии и патофизиологии; заведующий НИЛ альтернативных антимикробных биопрепаратов

ул. Академика Павлова, д. 12, Санкт-Петербург, Россия, 197376

Shamova Olga V., PhD, Corr. Member RAS – Deputy Director, Head of the Department of General Pathology and Pathophysiology; Head of the laboratory of Alternative Antimicrobial Biopreparations

Academician Pavlov str. 12, Saint Petersburg, Russia, 197376

shamova@iemspb.ruЖарковаМ. С.ZharkovaM. S.

Жаркова Мария Сергеевна, к.б.н., старший научный сотрудник отдела общей патологии и патофизиологии; старший научный сотрудник НИЛ альтернативных антимикробных биопрепаратов

Санкт-Петербург

Zharkova Maria S., PhD, Senior Researcher, Laboratory of Alternative Antimicrobial Biopreparations; Senior Researcher, Department of General Pathology and Pathophysiology

Saint Petersburg

ЧерновА. Н.ChernovA. N.

Чернов Александр Николаевич, научный сотрудник отдела микробной терапии; научный сотрудник отдела общей патологии и патофизиологии

Санкт-Петербург

Chernov Alexander N., Researcher, Department of Microbial Therapy; Researcher, Department of General Pathology and Pathophysiology

Saint Petersburg

ВладимироваЕ. В.VladimirovaE. V.

Владимирова Елизавета Васильевна, младший научный сотрудник НИЛ альтернативных антимикробных биопрепаратов

Санкт-Петербург

Vladimirova Elizaveta V., Junior Researcher, Laboratory of Alternative Antimicrobial Biopreparations

Saint Petersburg

СухареваМ. С.SukharevaM. S.

Сухарева Мария Сергеевна, младший научный сотрудник НИЛ альтернативных антимикробных биопрепаратов

Санкт-Петербург

Sukhareva Maria S., Junior Researcher, Laboratory of Alternative Antimicrobial Biopreparations

Saint Petersburg

КомлевА. С.KomlevA. S.

Комлев Алексей Сергеевич, младший научный сотрудник НИЛ альтернативных антимикробных биопрепаратов

Санкт-Петербург

Komlev Aleksey S., Junior Researcher, Laboratory of Alternative Antimicrobial Biopreparations

Saint Petersburg

КочендаО. Л.KochendaO. L.

Коченда Ольга Леонидовна, лаборант-исследователь отдела общей патологии и патофизиологии; лаборант-исследователь НИЛ альтернативных антимикробных биопрепаратов

Санкт-Петербург

Kochenda Olga L., Technician, Department of General Pathology and Pathophysiology; Research Laboratory Assistant at the Research Laboratory of Alternative Antimicrobial Biologicals

Saint Petersburg

ОрловД. С.OrlovD. S.

Орлов Дмитрий Сергеевич, к.м.н., доцент, заведующий лабораторией иммунопатофизиологии отдела общей патологии и патофизиологии

Санкт-Петербург

Orlov Dmitriy S., MD, PhD, Associate Professor, Head of the Laboratory of Immunepathophysiology, Department of General Pathology and Pathophysiology

Saint Petersburg

Научный центр мирового уровня «Центр персонализированной медицины»; Федеральное государственное бюджетное научное учреждение «Институт экспериментальной медицины»РоссияWorld-Class Research Center for Personalized Medicine; Institute of Experimental MedicineRussian FederationНаучный центр мирового уровня «Центр персонализированной медицины»РоссияWorld-Class Research Center for Personalized MedicineRussian FederationНаучный центр мирового уровня «Центр персонализированной медицины»; Федеральное государственное бюджетное научное учреждение «Институт экспериментальной медицины»РоссияWorld-Class Research Center for Personalized Medicine; Institute of Experimental Medicine; Institute of Experimental MedicineRussian FederationФедеральное государственное бюджетное научное учреждение «Институт экспериментальной медицины»РоссияInstitute of Experimental MedicineRussian Federation20212812202111146172Copyright © Шамова О.В., Жаркова М.С., Чернов А.Н., Владимирова Е.В., Сухарева М.С., Комлев А.С., Коченда О.Л., Орлов Д.С., 20212021Шамова О.В., Жаркова М.С., Чернов А.Н., Владимирова Е.В., Сухарева М.С., Комлев А.С., Коченда О.Л., Орлов Д.С.Shamova O.V., Zharkova M.S., Chernov A.N., Vladimirova E.V., Sukhareva M.S., Komlev A.S., Kochenda O.L., Orlov D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/11

В обзоре проводится анализ литературных данных об антимикробных пептидах (АМП) системы врожденного иммунитета как о перспективных прототипах новых антибиотических средств для преодоления антибиотикорезистентности микроорганизмов. Освещены структурно-функциональные свойства данных пептидов, приведены сведения о механизмах антимикробного действия и, кратко, об эффектах на клетки высших эукариот. Обсуждаются преимущества АМП по сравнению с конвенциональными антибиотиками и проблемы практического применения АМП. Приводятся примеры разработанных на основе АМП препаратов, находящихся на стадии клинических испытаний, обосновывается необходимость создания новых пептидных препаратов для применения в медицине в терапии инфекционных заболеваний, вызываемых устойчивыми к антибиотикам микроорганизмами.

The review represents the analysis of the literature data on antimicrobial peptides (AMPs) of the innate immune system as promising prototypes of new antibiotic agents for overcoming the antibiotic resistance of microorganisms. Structural and functional properties of these peptides are highlighted, information on the mechanisms of antimicrobial action and, briefly, on their effects on the cells of higher eukaryotes is provided. The advantages of AMPs in comparison with conventional antibiotics and the problems of practical application of AMPs are discussed. Examples of drugs developed based on AMPs that are at the stage of clinical trials are given, the necessity of creating new peptide drugs for medical application in the treatment of infectious diseases caused by antibiotic-resistant microorganisms is substantiated.

антибактериальное действиеантимикробные пептидыинфекционные заболеванияклинические испытаниямикробная резистентностьantibacterial actionantimicrobial peptidesclinical trialsinfectious diseasesmicrobial resistanceReferencesWorld Health Organization. No time to wait: Securing the future from drug-resistant infections — Report to the Secretary-General of the United Nations. 2019. https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf (4 October 2021).World Health Organization. No time to wait: Securing the future from drug-resistant infections — Report to the Secretary-General of the United Nations. 2019. https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf (4 October 2021).World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. 2017. https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12 (4 October 2021).World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. 2017. https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12 (4 October 2021).Jamal M, Ahmad W, Andleeb S, et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018; 81(1):7–11. DOI: 10.1016/j.jcma.2017.07.012.Jamal M, Ahmad W, Andleeb S, et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018; 81(1):7–11. DOI: 10.1016/j.jcma.2017.07.012.Vestby LK, Grønseth T, Simm R, et al. Bacterial Biofilm and its Role in the Pathogenesis of Disease. Antibiotics (Basel). 2020; 9(2):59. DOI: 10.3390/antibiotics9020059.Vestby LK, Grønseth T, Simm R, et al. Bacterial Biofilm and its Role in the Pathogenesis of Disease. Antibiotics (Basel). 2020; 9(2):59. DOI: 10.3390/antibiotics9020059.Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013; (136):1–51. DOI: 10.1111/apm.12099.Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013; (136):1–51. DOI: 10.1111/apm.12099.Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009; 30(3):131–141. DOI: 10.1016/j.it.2008.12.003.Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009; 30(3):131–141. DOI: 10.1016/j.it.2008.12.003.Riera Romo M, Pérez-Martínez D, Castillo Ferrer C. Innate immunity in vertebrates: an overview. Immunology. 2016; 148(2):125–139. DOI: 10.1111/imm.12597.Riera Romo M, Pérez-Martínez D, Castillo Ferrer C. Innate immunity in vertebrates: an overview. Immunology. 2016; 148(2):125–139. DOI: 10.1111/imm.12597.Kokryakov VN. Essays on innate immunity. Saint Petersburg: Nauka, 2006. 261 p. In Russian [Кокряков В.Н. Очерки о врождённом иммунитете. СПб: Наука, 2006. 261 c.].Kokryakov VN. Essays on innate immunity. Saint Petersburg: Nauka, 2006. 261 p. In RussianLi Y, Xiang Q, Zhang Q, et al. Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides. 2012; 37(2):207–215. DOI: 10.1016/j.peptides.2012.07.001.Li Y, Xiang Q, Zhang Q, et al. Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides. 2012; 37(2):207–215. DOI: 10.1016/j.peptides.2012.07.001.Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol. 2012; 32(2):143–171. DOI: 10.3109/07388551.2011.594423.Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol. 2012; 32(2):143–171. DOI: 10.3109/07388551.2011.594423.Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J Am Soc Nephrol. 2007; 18(11):2810–2816. DOI: 10.1681/ASN.2007050611.Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J Am Soc Nephrol. 2007; 18(11):2810–2816. DOI: 10.1681/ASN.2007050611.Nijnik A, Hancock R. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J. 2009; 2:e1. DOI: 10.3134/ehtj.09.001.Nijnik A, Hancock R. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J. 2009; 2:e1. DOI: 10.3134/ehtj.09.001.Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence. 2010; 1(5):440–464. DOI: 10.4161/viru.1.5.12983.Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence. 2010; 1(5):440–464. DOI: 10.4161/viru.1.5.12983.Lehrer RI, Lu W. α-Defensins in human innate immunity. Immunol Rev. 2012; 245(1):84–112. DOI: 10.1111/j.1600-065X.2011.01082.x.Lehrer RI, Lu W. α-Defensins in human innate immunity. Immunol Rev. 2012; 245(1):84–112. DOI: 10.1111/j.1600-065X.2011.01082.x.Wang G. Antimicrobial peptides: Discovery, design, and novel therapeutic strategies. Wallingford: CABI Publishing, 2010. 230 p.Wang G. Antimicrobial peptides: Discovery, design, and novel therapeutic strategies. Wallingford: CABI Publishing, 2010. 230 p.Mookherjee N, Anderson MA, Haagsman HP, et al. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020; 19(5):311–332. DOI: 10.1038/s41573-019-0058-8.Mookherjee N, Anderson MA, Haagsman HP, et al. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020; 19(5):311–332. DOI: 10.1038/s41573-019-0058-8.Pachón-Ibáñez ME, Smani Y, Pachón J, et al. Perspectives for clinical use of engineered human host defense antimicrobial peptides. FEMS Microbiol Rev. 2017; 41(3):323–342. DOI: 10.1093/femsre/fux012.Pachón-Ibáñez ME, Smani Y, Pachón J, et al. Perspectives for clinical use of engineered human host defense antimicrobial peptides. FEMS Microbiol Rev. 2017; 41(3):323–342. DOI: 10.1093/femsre/fux012.Huan Y, Kong Q, Mou H, et al. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front Microbiol. 2020; 11:582779. DOI: 10.3389/fmicb.2020.582779.Huan Y, Kong Q, Mou H, et al. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front Microbiol. 2020; 11:582779. DOI: 10.3389/fmicb.2020.582779.Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011; 29(9):464–472. DOI: 10.1016/j.tibtech.2011.05.001.Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011; 29(9):464–472. DOI: 10.1016/j.tibtech.2011.05.001.Kumar P, Kizhakkedathu JN, Straus SK. Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. Biomolecules. 2018; 8(1):4. DOI: 10.3390/biom8010004.Kumar P, Kizhakkedathu JN, Straus SK. Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. Biomolecules. 2018; 8(1):4. DOI: 10.3390/biom8010004.Harris F, Dennison SR, Phoenix DA. Anionic antimicrobial peptides from eukaryotic organisms. Curr Protein Pept Sci. 2009; 10(6):585–606. DOI: 10.2174/138920309789630589.Harris F, Dennison SR, Phoenix DA. Anionic antimicrobial peptides from eukaryotic organisms. Curr Protein Pept Sci. 2009; 10(6):585–606. DOI: 10.2174/138920309789630589.Phoenix DA, Dennison SR, Harris F. Antimicrobial Peptides. Singapore: Wiley-VCH, 2013. 231 p.Phoenix DA, Dennison SR, Harris F. Antimicrobial Peptides. Singapore: Wiley-VCH, 2013. 231 p.Lai R, Liu H, Hui Lee W, et al. An anionic antimicrobial peptide from toad Bombina maxima. Biochem Biophys Res Commun. 2002; 295(4):796–799. DOI: 10.1016/s0006-291x(02)00762-3.Lai R, Liu H, Hui Lee W, et al. An anionic antimicrobial peptide from toad Bombina maxima. Biochem Biophys Res Commun. 2002; 295(4):796–799. DOI: 10.1016/s0006-291x(02)00762-3.Dorin JR, McHugh BJ, Cox SL, et al. Chapter 30—Mammalian Antimicrobial Peptides; Defensins and Cathelicidins. In: Tang Y-W, Sussman M, Liu D, et al. eds. Molecular Medical Microbiology. 2nd ed. Cambridge, MA, USA: Academic Press, 2015:539–565. DOI: 10.1016/B978-0-12-397169-2.00030-5.Dorin JR, McHugh BJ, Cox SL, et al. Chapter 30—Mammalian Antimicrobial Peptides; Defensins and Cathelicidins. In: Tang Y-W, Sussman M, Liu D, et al. eds. Molecular Medical Microbiology. 2nd ed. Cambridge, MA, USA: Academic Press, 2015:539–565. DOI: 10.1016/B978-0-12-397169-2.00030-5.Zeya HI, Spitznagel JK. Antibacterial and enzymatic basic protein from leukocyte lysosomes: separation and identification. Science. 1963; 142(3595):1085–1087. DOI: 10.1126/science.142.3595.1085.Zeya HI, Spitznagel JK. Antibacterial and enzymatic basic protein from leukocyte lysosomes: separation and identification. Science. 1963; 142(3595):1085–1087. DOI: 10.1126/science.142.3595.1085.Ашмарин И.П., Кокряков В.Н., Лызлова С.Н., и др. Взаимодействие катионных белков гранул и миелоперoксидазы лейкоцитов. Вопросы медицинской химии (Биомедицинская химия с 2003). 1977; 3:534–537.Ashmarin IP, Kokryakov VN, Lyzlova SN, et al. Interaction of cationic proteins of granules and myeloperoxidase of leukocytes. Problems of medicinal chemistry (Biomedical chemistry since 2003). 1977; 3:534–537. In RussianКокряков В.Н., Ашмарин И.П., Пигаревский В.Е. О природе некоторых фракций лизосомальных катионных белков лейкоцитов. Биохимия. 1973; 38(6):1276–1280.Kokryakov VN, Ashmarin IP, Pigarevsky VE. On the nature of some fractions of lysosomal cationic proteins of leukocytes. Biochemistry. 1973; 38(6):1276–Мазинг Ю.А. Нейтрофильные гранулоциты и система защиты организма. Архив патологии. 1991; 9:70–73.In RussianПигаревский В.Е., Ашмарин И.П., Толыбеков А.С., и др. О влиянии in vitro лейкоцитарного и тимусного гитона и их фракций на активность возбудителя менингопневмонии. Журнал микробиологии, эпидемиологии и иммунобиологии. 1975; 10:76–78.Masing YuA. Neutrophilic granulocytes and the body’s defense system. Archive of pathology. 1991; 9:70–73. In RussianПигаревский В.Е, Кокряков В.Н., Тарос Л.Ю., и др. Антивирусные свойства дефенсинов при экспериментальной герпетической инфекции. В кн.: Патоморфология опухолей и фоновых заболева- ний. Л., 1989: 122–124.Pigarevsky VE, Ashmarin IP, Tolybekov AS, et al. On the in vitro effect of leukocyte and thymic giton and their fractions on the activity of the causative agent of meningopneumonia. Journal of Microbiology, Epidemiology and Immunobiology. 1975; 10:76–78. In RussianGanz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985; 76(4):1427–1435. DOI: 10.1172/JCI112120.Pigarevsky VE, Kokryakov VN, Taros LYu, et al. Antiviral properties of defensins in experimental herpes infection. In: Pathomorphology of tumors and background diseases. Leningrad, 1989:122–Selsted ME, Brown DM, DeLange RJ, et al. Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem. 1985; 260(8):4579–4584.In RussianSelsted ME, Harwig SS, Ganz T, et al. Primary structures of three human neutrophil defensins. J Clin Invest. 1985; 76(4):1436–1439. DOI: 10.1172/JCI112121.Ganz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985; 76(4):1427–1435. DOI: 10.1172/JCI112120.Selsted ME, Harwig SS. Purification, primary structure, and antimicrobial activities of a guinea pig neutrophil defensin. Infect Immun. 1987; 55(9):2281–2286. DOI: 10.1128/iai.55.9.2281-2286.1987.Selsted ME, Brown DM, DeLange RJ, et al. Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem. 1985; 260(8):4579–4584.Eisenhauer PB, Harwig SS, Szklarek D, et al. Purification and antimicrobial properties of three defensins from rat neutrophils. Infect Immun. 1989; 57(7):2021–2027. DOI: 10.1128/iai.57.7.2021-2027.1989.Selsted ME, Harwig SS, Ganz T, et al. Primary structures of three human neutrophil defensins. J Clin Invest. 1985; 76(4):1436–1439. DOI: 10.1172/JCI112121.Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 2000; 96(9):3086–3093.Selsted ME, Harwig SS. Purification, primary structure, and antimicrobial activities of a guinea pig neutrophil defensin. Infect Immun. 1987; 55(9):2281–2286. DOI: 10.1128/iai.55.9.2281-2286.1987.Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005; 6(6):551–557. DOI: 10.1038/ni1206.Eisenhauer PB, Harwig SS, Szklarek D, et al. Purification and antimicrobial properties of three defensins from rat neutrophils. Infect Immun. 1989; 57(7):2021–2027. DOI: 10.1128/iai.57.7.2021-2027.1989.Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem. 1992; 267(32):23216–23225.Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 2000; 96(9):3086–3093.Valore EV, Park CH, Quayle AJ, et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest. 1998; 101(8):1633–1642. DOI: 10.1172/JCI1861.Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005; 6(6):551–557. DOI: 10.1038/ni1206.Nakayama K, Okamura N, Arai H, et al. Expression of human beta-defensin-1 in the choroid plexus. Ann Neurol. 1999; 45(5):685. DOI: 10.1002/1531-8249(199905)45:5<685::aid-ana25>3.0.co;2-6.Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem. 1992; 267(32):23216–23225.McCray PB Jr, Bentley L. Human airway epithelia express a beta-defensin. Am J Respir Cell Mol Biol. 1997; 16(3):343–349. DOI: 10.1165/ajrcmb.16.3.9070620.Valore EV, Park CH, Quayle AJ, et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest. 1998; 101(8):1633–1642. DOI: 10.1172/JCI1861.Harder J, Bartels J, Christophers E, et al. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem. 2001; 276(8):5707–5713. DOI: 10.1074/jbc.M008557200.Nakayama K, Okamura N, Arai H, et al. Expression of human beta-defensin-1 in the choroid plexus. Ann Neurol. 1999; 45(5):685. DOI: 10.1002/1531-8249(199905)45:5<685::aid-ana25>3.0.co;2-6.Ghosh SK, Gerken TA, Schneider KM, et al. Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem. 2007; 53(4):757–765. DOI: 10.1373/clinchem.2006.081430.McCray PB Jr, Bentley L. Human airway epithelia express a beta-defensin. Am J Respir Cell Mol Biol. 1997; 16(3):343–349. DOI: 10.1165/ajrcmb.16.3.9070620.Shestakova T, Zhuravel E, Bolgova L, et al. Expression of human beta-defensins-1, 2 and 4 mRNA in human lung tumor tissue: a pilot study. Exp Oncol. 2008; 30(2):153–156.Harder J, Bartels J, Christophers E, et al. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem. 2001; 276(8):5707–5713. DOI: 10.1074/jbc.M008557200.Otte JM, Neumann HM, Brand S, et al. Expression of beta-defensin 4 is increased in human gastritis. Eur J Clin Invest. 2009; 39(2):126–138. DOI: 10.1111/j.1365-2362.2008.02071.x.Ghosh SK, Gerken TA, Schneider KM, et al. Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem. 2007; 53(4):757–765. DOI: 10.1373/clinchem.2006.081430.Pazgier M, Hoover DM, Yang D, et al. Human beta-defensins. Cell Mol Life Sci. 2006; 63(11):1294–1313. DOI: 10.1007/s00018-005-5540-2.Shestakova T, Zhuravel E, Bolgova L, et al. Expression of human beta-defensins-1, 2 and 4 mRNA in human lung tumor tissue: a pilot study. Exp Oncol. 2008; 30(2):153–156.Tang YQ, Yuan J, Osapay G, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science. 1999; 286(5439):498–502. DOI: 10.1126/science.286.5439.498.Otte JM, Neumann HM, Brand S, et al. Expression of beta-defensin 4 is increased in human gastritis. Eur J Clin Invest. 2009; 39(2):126–138. DOI: 10.1111/j.1365-2362.2008.02071.x.Leonova L, Kokryakov VN, Aleshina G, et al. Circular minidefensins and posttranslational generation of molecular diversity. J Leukoc Biol. 2001; 70(3):461–464.Pazgier M, Hoover DM, Yang D, et al. Human beta-defensins. Cell Mol Life Sci. 2006; 63(11):1294–1313. DOI: 10.1007/s00018-005-5540-2.Stegemann C, Tsvetkova EV, Aleshina GM, et al. De novo sequencing of two new cyclic theta-defensins from baboon (Papio hamadryas) leukocytes by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 2010; 24(5):599–604. DOI: 10.1002/rcm.4424.Tang YQ, Yuan J, Osapay G, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science. 1999; 286(5439):498–502. DOI: 10.1126/science.286.5439.498.Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995; 374(1):1–5. DOI: 10.1016/0014-5793(95)01050-o.Leonova L, Kokryakov VN, Aleshina G, et al. Circular minidefensins and posttranslational generation of molecular diversity. J Leukoc Biol. 2001; 70(3):461–464.Kopitar M, Ritonja A, Popovic T, et al. A new type of low-molecular mass cysteine proteinase inhibitor from pig leukocytes. Biol Chem Hoppe Seyler. 1989; 370(10):1145–1151. DOI: 10.1515/bchm3.1989.370.2.1145.Stegemann C, Tsvetkova EV, Aleshina GM, et al. De novo sequencing of two new cyclic theta-defensins from baboon (Papio hamadryas) leukocytes by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 2010; 24(5):599–604. DOI: 10.1002/rcm.4424.Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 2005; 7(2):179–196.Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995; 374(1):1–5. DOI: 10.1016/0014-5793(95)01050-o.Kościuczuk EM, Lisowski P, Jarczak J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep. 2012; 39(12):10957–10970. DOI: 10.1007/s11033-012-1997-x.Kopitar M, Ritonja A, Popovic T, et al. A new type of low-molecular mass cysteine proteinase inhibitor from pig leukocytes. Biol Chem Hoppe Seyler. 1989; 370(10):1145–1151. DOI: 10.1515/bchm3.1989.370.2.1145.Wang Y, Wang M, Shan A, et al. Avian host defense cathelicidins: structure, expression, biological functions, and potential therapeutic applications. Poult Sci. 2020; 99(12):6434–6445. DOI: 10.1016/j.psj.2020.09.030.Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 2005; 7(2):179–196.Graf M, Wilson DN. Intracellular Antimicrobial Peptides Targeting the Protein Synthesis Machinery. Adv Exp Med Biol. 2019; 1117:73–89. DOI: 10.1007/978-981-13-3588-4_6.Kościuczuk EM, Lisowski P, Jarczak J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep. 2012; 39(12):10957–10970. DOI: 10.1007/s11033-012-1997-x.Mercer DK, O’Neil DA. Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response. Front Immunol. 2020; 11:2177. DOI: 10.3389/fimmu.2020.02177.Wang Y, Wang M, Shan A, et al. Avian host defense cathelicidins: structure, expression, biological functions, and potential therapeutic applications. Poult Sci. 2020; 99(12):6434–6445. DOI: 10.1016/j.psj.2020.09.030.Mechkarska M, Ahmed E, Coquet L, et al. Antimicrobial peptides with therapeutic potential from skin secretions of the Marsabit clawed frog Xenopus borealis (Pipidae). Comp Biochem Physiol C Toxicol Pharmacol. 2010; 152(4):467–472. DOI: 10.1016/j.cbpc.2010.07.007.Graf M, Wilson DN. Intracellular Antimicrobial Peptides Targeting the Protein Synthesis Machinery. Adv Exp Med Biol. 2019; 1117:73–89. DOI: 10.1007/978-981-13-3588-4_6.Wang J, Wong ES, Whitley JC, et al. Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options. PLoS One. 2011; 6(8):e24030. DOI: 10.1371/journal.pone.0024030.Mercer DK, O’Neil DA. Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response. Front Immunol. 2020; 11:2177. DOI: 10.3389/fimmu.2020.02177.Roque-Borda CA, da Silva PB, Rodrigues MC, et al. Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria. Pharmaceutics. 2021; 13(6):773. DOI: 10.3390/pharmaceutics13060773.Mechkarska M, Ahmed E, Coquet L, et al. Antimicrobial peptides with therapeutic potential from skin secretions of the Marsabit clawed frog Xenopus borealis (Pipidae). Comp Biochem Physiol C Toxicol Pharmacol. 2010; 152(4):467–472. DOI: 10.1016/j.cbpc.2010.07.007.León-Buitimea A, Garza-Cárdenas CR, Garza- Cervantes JA, et al. The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design. Front Microbiol. 2020; 11:1669. DOI: 10.3389/fmicb.2020.01669.Wang J, Wong ES, Whitley JC, et al. Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options. PLoS One. 2011; 6(8):e24030. DOI: 10.1371/journal.pone.0024030.Lohner K. New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys. 2009; 28(2):105–116. DOI: 10.4149/gpb_2009_02_105.Roque-Borda CA, da Silva PB, Rodrigues MC, et al. Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria. Pharmaceutics. 2021; 13(6):773. DOI: 10.3390/pharmaceutics13060773.Hollmann A, Martinez M, Maturana P, et al. Antimicrobial Peptides: Interaction With Model and Biological Membranes and Synergism With Chemical Antibiotics. Front Chem. 2018; 6:204. DOI: 10.3389/fchem.2018.00204.León-Buitimea A, Garza-Cárdenas CR, Garza- Cervantes JA, et al. The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design. Front Microbiol. 2020; 11:1669. DOI: 10.3389/fmicb.2020.01669.Tornesello AL, Borrelli A, Buonaguro L, et al. Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities. Molecules. 2020; 25(12):2850. DOI: 10.3390/molecules25122850.Lohner K. New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys. 2009; 28(2):105–116. DOI: 10.4149/gpb_2009_02_105.Li J, Koh JJ, Liu S, et al. Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. Front Neurosci. 2017; 11:73. doi: 10.3389/fnins.2017.00073.Hollmann A, Martinez M, Maturana P, et al. Antimicrobial Peptides: Interaction With Model and Biological Membranes and Synergism With Chemical Antibiotics. Front Chem. 2018; 6:204. DOI: 10.3389/fchem.2018.00204.Tuerkova A, Kabelka I, Králová T, et al. Effect of helical kink in antimicrobial peptides on membrane pore formation. Elife. 2020; 9:e47946. DOI: 10.7554/eLife.47946.Tornesello AL, Borrelli A, Buonaguro L, et al. Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities. Molecules. 2020; 25(12):2850. DOI: 10.3390/molecules25122850.Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005; 3(3):238–250. DOI: 10.1038/nrmicro1098.Li J, Koh JJ, Liu S, et al. Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. Front Neurosci. 2017; 11:73. doi: 10.3389/fnins.2017.00073.Pouny Y, Rapaport D, Mor A, et al. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry. 1992; 31(49):12416–12423. DOI: 10.1021/bi00164a017.Tuerkova A, Kabelka I, Králová T, et al. Effect of helical kink in antimicrobial peptides on membrane pore formation. Elife. 2020; 9:e47946. DOI: 10.7554/eLife.47946.Miteva M, Andersson M, Karshikoff A, et al. Molecular electroporation: a unifying concept for the description of membrane pore formation by antibacterial peptides, exemplified with NK-lysin. FEBS Lett. 1999; 462(1–2):155–158. DOI: 10.1016/s0014-5793(99)01520-3.Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005; 3(3):238–250. DOI: 10.1038/nrmicro1098.Le CF, Fang CM, Sekaran SD. Intracellular Targeting Mechanisms by Antimicrobial Peptides. Antimicrob Agents Chemother. 2017; 61(4):e02340-16. DOI: 10.1128/AAC.02340-16.Pouny Y, Rapaport D, Mor A, et al. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry. 1992; 31(49):12416–12423. DOI: 10.1021/bi00164a017.Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998; 244(1):253–257. DOI: 10.1006/bbrc.1998.8159.Miteva M, Andersson M, Karshikoff A, et al. Molecular electroporation: a unifying concept for the description of membrane pore formation by antibacterial peptides, exemplified with NK-lysin. FEBS Lett. 1999; 462(1–2):155–158. DOI: 10.1016/s0014-5793(99)01520-3.Patrzykat A, Friedrich CL, Zhang L, et al. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother. 2002; 46(3):605–614. DOI: 10.1128/AAC.46.3.605-614.2002.Le CF, Fang CM, Sekaran SD. Intracellular Targeting Mechanisms by Antimicrobial Peptides. Antimicrob Agents Chemother. 2017; 61(4):e02340-16. DOI: 10.1128/AAC.02340-16.Lehrer RI, Barton A, Daher KA, et al. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest. 1989; 84(2):553–561. DOI: 10.1172/JCI114198 .Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998; 244(1):253–257. DOI: 10.1006/bbrc.1998.8159.Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett. 1998; 160(1):91–96. DOI: 10.1111/j.1574-6968.1998.tb12896.x.Patrzykat A, Friedrich CL, Zhang L, et al. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother. 2002; 46(3):605–614. DOI: 10.1128/AAC.46.3.605-614.2002.Kragol G, Lovas S, Varadi G, et al. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry. 2001; 40(10):3016–3026. DOI: 10.1021/bi002656a.Lehrer RI, Barton A, Daher KA, et al. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest. 1989; 84(2):553–561. DOI: 10.1172/JCI114198 .Scocchi M, Lüthy C, Decarli P, et al. The Proline- rich Antibacterial Peptide Bac7 Binds to and Inhibits in vitro the Molecular Chaperone DnaK. Int J Pept Res Therapeut. 2009; 15(2):147–155. DOI: 10.1007/s10989-009-9182-3.Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett. 1998; 160(1):91–96. DOI: 10.1111/j.1574-6968.1998.tb12896.x.Zahn M, Berthold N, Kieslich B, et al. Structural studies on the forward and reverse binding modes of peptides to the chaperone DnaK. J Mol Biol. 2013; 425(14):2463–2479. DOI: 10.1016/j.jmb.2013.03.041.Kragol G, Lovas S, Varadi G, et al. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry. 2001; 40(10):3016–3026. DOI: 10.1021/bi002656a.Zahn M, Kieslich B, Berthold N, et al. Structural identification of DnaK binding sites within bovine and sheep bactenecin Bac7. Protein Pept Lett. 2014; 21:407–412. DOI: 10.2174/09298665113206660111.Scocchi M, Lüthy C, Decarli P, et al. The Proline- rich Antibacterial Peptide Bac7 Binds to and Inhibits in vitro the Molecular Chaperone DnaK. Int J Pept Res Therapeut. 2009; 15(2):147–155. DOI: 10.1007/s10989-009-9182-3.Krizsan A, Prahl C, Goldbach T, et al. Short proline-rich antimicrobial peptides inhibit either the bacterial 70S ribosome or the assembly of its large 50S subunit. Chembiochem. 2015; 16(16):2304–2308. DOI: 10.1002/cbic.201500375.Zahn M, Berthold N, Kieslich B, et al. Structural studies on the forward and reverse binding modes of peptides to the chaperone DnaK. J Mol Biol. 2013; 425(14):2463–2479. DOI: 10.1016/j.jmb.2013.03.041.Krizsan A, Volke D, Weinert S, et al. Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. Angew Chem Int Ed Engl. 2014; 53:12236–12239. DOI: 10.1002/anie.201407145.Zahn M, Kieslich B, Berthold N, et al. Structural identification of DnaK binding sites within bovine and sheep bactenecin Bac7. Protein Pept Lett. 2014; 21:407–412. DOI: 10.2174/09298665113206660111.Roy RN, Lomakin IB, Gagnon MG, et al. The mechanism of inhibition of protein synthesis by the proline-rich peptide oncocin. Nat Struct Mol Biol. 2015; 22:466–469. DOI: 10.1038/nsmb.3031.Krizsan A, Prahl C, Goldbach T, et al. Short proline-rich antimicrobial peptides inhibit either the bacterial 70S ribosome or the assembly of its large 50S subunit. Chembiochem. 2015; 16(16):2304–2308. DOI: 10.1002/cbic.201500375.Mardirossian M, Grzela R, Giglione C, et al. The host antimicrobial peptide Bac71-35 binds to bacterial ribosomal proteins and inhibits protein synthesis. Chem Biol. 2014; 21:1639–1647. DOI: 10.1016/j.chembiol.2014.10.009.Krizsan A, Volke D, Weinert S, et al. Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. Angew Chem Int Ed Engl. 2014; 53:12236–12239. DOI: 10.1002/anie.201407145.Mardirossian M, Barrière Q, Timchenko T, et al. Fragments of the Nonlytic Proline-Rich Antimicrobial Peptide Bac5 Kill Escherichia coli Cells by Inhibiting Protein Synthesis. Antimicrob Agents Chemother. 2018; 62(8):e00534-18. DOI: 10.1128/AAC.00534-18.Roy RN, Lomakin IB, Gagnon MG, et al. The mechanism of inhibition of protein synthesis by the proline-rich peptide oncocin. Nat Struct Mol Biol. 2015; 22:466–469. DOI: 10.1038/nsmb.3031.Brötz H, Bierbaum G, Reynolds PE, et al. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem. 1997; 246(1):193-199. DOI: 10.1111/j.1432-1033.1997.t01-1-00193.x.Mardirossian M, Grzela R, Giglione C, et al. The host antimicrobial peptide Bac71-35 binds to bacterial ribosomal proteins and inhibits protein synthesis. Chem Biol. 2014; 21:1639–1647. DOI: 10.1016/j.chembiol.2014.10.009.Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov. 2006; 5(4):321–332. DOI: 10.1038/nrd2004.Mardirossian M, Barrière Q, Timchenko T, et al. Fragments of the Nonlytic Proline-Rich Antimicrobial Peptide Bac5 Kill Escherichia coli Cells by Inhibiting Protein Synthesis. Antimicrob Agents Chemother. 2018; 62(8):e00534-18. DOI: 10.1128/AAC.00534-18.Liu SP, Zhou L, Lakshminarayanan R, et al. Multivalent Antimicrobial Peptides as Therapeutics: Design Principles and Structural Diversities. Int J Pept Res Ther. 2010; 16(3):199–213. DOI: 10.1007/s10989-010-9230-z.Brötz H, Bierbaum G, Reynolds PE, et al. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem. 1997; 246(1):193-199. DOI: 10.1111/j.1432-1033.1997.t01-1-00193.x.Guilhelmelli F, Vilela N, Albuquerque P, et al. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol. 2013; 4:353. DOI: 10.3389/fmicb.2013.00353.Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov. 2006; 5(4):321–332. DOI: 10.1038/nrd2004.Boehr DD, Draker KA, Koteva K, et al. Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chem Biol. 2003; 10(2):189–196. DOI: 10.1016/s1074-5521(03)00026-7.Liu SP, Zhou L, Lakshminarayanan R, et al. Multivalent Antimicrobial Peptides as Therapeutics: Design Principles and Structural Diversities. Int J Pept Res Ther. 2010; 16(3):199–213. DOI: 10.1007/s10989-010-9230-z.Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011; 239(1–2):27–34. DOI: 10.1007/s00232-011-9343-0.Guilhelmelli F, Vilela N, Albuquerque P, et al. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol. 2013; 4:353. DOI: 10.3389/fmicb.2013.00353.Lichtenstein AK, Ganz T, Nguyen TM, et al. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J Immunol. 1988; 140(8):2686–2694.Boehr DD, Draker KA, Koteva K, et al. Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chem Biol. 2003; 10(2):189–196. DOI: 10.1016/s1074-5521(03)00026-7.Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest. 1991; 88(1):93–100. DOI: 10.1172/JCI115310.Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011; 239(1–2):27–34. DOI: 10.1007/s00232-011-9343-0.McKeown ST, Lundy FT, Nelson J, et al. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 2006; 42(7):685–690. DOI: 10.1016/j.oraloncology.2005.11.005.Lichtenstein AK, Ganz T, Nguyen TM, et al. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J Immunol. 1988; 140(8):2686–2694.Huang HJ, Ross CR, Blecha F. Chemoattractant properties of PR-39, a neutrophil antibacterial peptide. J Leukoc Biol. 1997; 61(5):624–629. DOI: 10.1002/jlb.61.5.624.Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest. 1991; 88(1):93–100. DOI: 10.1172/JCI115310.Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001; 167(11):6644–6653. DOI: 10.4049/jimmunol.167.11.6644.McKeown ST, Lundy FT, Nelson J, et al. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 2006; 42(7):685–690. DOI: 10.1016/j.oraloncology.2005.11.005.Dürr M, Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun. 2002; 70(12):6515–6517. DOI: 10.1128/IAI.70.12.6515-6517.2002.Huang HJ, Ross CR, Blecha F. Chemoattractant properties of PR-39, a neutrophil antibacterial peptide. J Leukoc Biol. 1997; 61(5):624–629. DOI: 10.1002/jlb.61.5.624.Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. Nat Med. 2000; 6(1):49–55. DOI: 10.1038/71527.Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001; 167(11):6644–6653. DOI: 10.4049/jimmunol.167.11.6644.Kanazawa K, Okumura K, Ogawa H, et al. An antimicrobial peptide with angiogenic properties, AG- 30/5C, activates human mast cells through the MAPK and NF-κB pathways. Immunol Res. 2016; 64(2):594–603. DOI: 10.1007/s12026-015-8759-5.Dürr M, Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun. 2002; 70(12):6515–6517. DOI: 10.1128/IAI.70.12.6515-6517.2002.Koczulla R, Bals R. Cathelicidin antimicrobial peptides modulate angiogenesis. In: E. Deindl and C. Kupatt eds. Therapeutic Neovascularization-Quo Vadis? Netherlands: Springer, 2007:191–196. DOI: 10.1007/1-4020-5955-8_10.Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. Nat Med. 2000; 6(1):49–55. DOI: 10.1038/71527.Takahashi M, Umehara Y, Yue H, et al. The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway. Front Immunol. 2021; 12:712781. DOI: 10.3389/fimmu.2021.712781.Kanazawa K, Okumura K, Ogawa H, et al. An antimicrobial peptide with angiogenic properties, AG- 30/5C, activates human mast cells through the MAPK and NF-κB pathways. Immunol Res. 2016; 64(2):594–603. DOI: 10.1007/s12026-015-8759-5.Territo MC, Ganz T, Selsted ME, et al. Monocyte- chemotactic activity of defensins from human neutrophils. J Clin Invest. 1989; 84(6):2017–2020. DOI: 10.1172/JCI114394.Koczulla R, Bals R. Cathelicidin antimicrobial peptides modulate angiogenesis. In: E. Deindl and C. Kupatt eds. Therapeutic Neovascularization-Quo Vadis? Netherlands: Springer, 2007:191–196. DOI: 10.1007/1-4020-5955-8_10.Niyonsaba F, Someya A, Hirata M, et al. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol. 2001; 31(4):1066–1075. DOI: 10.1002/1521-4141(200104)31:4<1066::aid-immu1066>3.0.co;2-#.Takahashi M, Umehara Y, Yue H, et al. The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway. Front Immunol. 2021; 12:712781. DOI: 10.3389/fimmu.2021.712781.Yoshioka M, Fukuishi N, Kubo Y, et al. Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol Pharm Bull. 2008; 31(2):212–216. DOI: 10.1248/bpb.31.212.Territo MC, Ganz T, Selsted ME, et al. Monocyte- chemotactic activity of defensins from human neutrophils. J Clin Invest. 1989; 84(6):2017–2020. DOI: 10.1172/JCI114394.Gupta K, Kotian A, Subramanian H, et al. Activation of human mast cells by retrocyclin and protegrin highlight their immunomodulatory and antimicrobial properties. Oncotarget. 2015; 6(30):28573–28587. DOI: 10.18632/oncotarget.5611.Niyonsaba F, Someya A, Hirata M, et al. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol. 2001; 31(4):1066–1075. DOI: 10.1002/1521-4141(200104)31:4<1066::aid-immu1066>3.0.co;2-#.Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol. 2004; 172(2):1146–1156. DOI: 10.4049/jimmunol.172.2.1146.Yoshioka M, Fukuishi N, Kubo Y, et al. Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol Pharm Bull. 2008; 31(2):212–216. DOI: 10.1248/bpb.31.212.Fu L, Jin P, Hu Y, et al. KR12a6 promotes the osteogenic differentiation of human bone marrow mesenchymal stem cells via BMP/SMAD signaling. Mol Med Rep. 2020; 21(1):61–68. DOI: 10.3892/mmr.2019.10843.Gupta K, Kotian A, Subramanian H, et al. Activation of human mast cells by retrocyclin and protegrin highlight their immunomodulatory and antimicrobial properties. Oncotarget. 2015; 6(30):28573–28587. DOI: 10.18632/oncotarget.5611.van der Does AM, Joosten SA, Vroomans E, et al. The antimicrobial peptide hLF1-11 drives monocyte- dendritic cell differentiation toward dendritic cells that promote antifungal responses and enhance Th17 polarization. J Innate Immun. 2012; 4(3):284–292. DOI: 10.1159/000332941.Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol. 2004; 172(2):1146–1156. DOI: 10.4049/jimmunol.172.2.1146.Zhu QZ, Hu J, Mulay S, et al. Isolation and structure of corticostatin peptides from rabbit fetal and adult lung. Proc Natl Acad Sci U S A. 1988; 85(2):592–596. DOI: 10.1073/pnas.85.2.592.Fu L, Jin P, Hu Y, et al. KR12a6 promotes the osteogenic differentiation of human bone marrow mesenchymal stem cells via BMP/SMAD signaling. Mol Med Rep. 2020; 21(1):61–68. DOI: 10.3892/mmr.2019.10843.Zhu Q, Solomon S. Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides. Endocrinology. 1992; 130(3):1413–1423. DOI: 10.1210/endo.130.3.1311240.van der Does AM, Joosten SA, Vroomans E, et al. The antimicrobial peptide hLF1-11 drives monocyte- dendritic cell differentiation toward dendritic cells that promote antifungal responses and enhance Th17 polarization. J Innate Immun. 2012; 4(3):284–292. DOI: 10.1159/000332941.Zhu QZ, Singh AV, Bateman A, et al. The corticostatic (anti-ACTH) and cytotoxic activity of peptides isolated from fetal, adult and tumor-bearing lung. J Steroid Biochem. 1987; 27(4–6):1017–1022. DOI: 10.1016/0022-4731(87)90184-1.Zhu QZ, Hu J, Mulay S, et al. Isolation and structure of corticostatin peptides from rabbit fetal and adult lung. Proc Natl Acad Sci U S A. 1988; 85(2):592–596. DOI: 10.1073/pnas.85.2.592.Cho JH, Kim SC. Non-membrane targets of antimicrobial peptides: novel therapeutic opportunities? In: Wang G, ed. Antimicrobial peptides: discovery, design and novel therapeutic strategies. Wallingford: CABI Publishing, 2010: 128–140.Zhu Q, Solomon S. Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides. Endocrinology. 1992; 130(3):1413–1423. DOI: 10.1210/endo.130.3.1311240.Mangoni ML. Host-defense peptides: from biology to therapeutic strategies. Cell Mol Life Sci. 2011; 68(13):2157–2159. DOI: 10.1007/s00018-011-0709-3.Zhu QZ, Singh AV, Bateman A, et al. The corticostatic (anti-ACTH) and cytotoxic activity of peptides isolated from fetal, adult and tumor-bearing lung. J Steroid Biochem. 1987; 27(4–6):1017–1022. DOI: 10.1016/0022-4731(87)90184-1.Alba A, López-Abarrategui C, Otero-González AJ. Host defense peptides: an alternative as antiinfective and immunomodulatory therapeutics. Biopolymers. 2012; 98(4):251–267. DOI: 10.1002/bip.22076.Cho JH, Kim SC. Non-membrane targets of antimicrobial peptides: novel therapeutic opportunities? In: Wang G, ed. Antimicrobial peptides: discovery, design and novel therapeutic strategies. Wallingford: CABI Publishing, 2010: 128–140.Deslouches B, Steckbeck JD, Craigo JK, et al. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob Agents Chemother. 2013; 57(6):2511–2521. DOI: 10.1128/AAC.02218-12.Mangoni ML. Host-defense peptides: from biology to therapeutic strategies. Cell Mol Life Sci. 2011; 68(13):2157–2159. DOI: 10.1007/s00018-011-0709-3.Kang SJ, Park SJ, Mishig-Ochir T, et al. Antimicrobial peptides: therapeutic potentials. Expert Rev Anti Infect Ther. 2014; 12(12):1477–1486. DOI: 10.1586/14787210.2014.976613.Alba A, López-Abarrategui C, Otero-González AJ. Host defense peptides: an alternative as antiinfective and immunomodulatory therapeutics. Biopolymers. 2012; 98(4):251–267. DOI: 10.1002/bip.22076.Mwangi J, Hao X, Lai R, et al. Antimicrobial peptides: new hope in the war against multidrug resistance. Zool Res. 2019; 40(6):488–505. DOI: 10.24272/j.issn.2095-8137.2019.062.Deslouches B, Steckbeck JD, Craigo JK, et al. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob Agents Chemother. 2013; 57(6):2511–2521. DOI: 10.1128/AAC.02218-12.Pletzer D, Hancock RE. Antibiofilm Peptides: Potential as Broad-Spectrum Agents. J Bacteriol. 2016; 198(19):2572–2578. DOI: 10.1128/JB.00017-16.Kang SJ, Park SJ, Mishig-Ochir T, et al. Antimicrobial peptides: therapeutic potentials. Expert Rev Anti Infect Ther. 2014; 12(12):1477–1486. DOI: 10.1586/14787210.2014.976613.Yasir M, Willcox MDP, Dutta D. Action of Antimicrobial Peptides against Bacterial Biofilms. Materials (Basel). 2018; 11(12):2468. DOI: 10.3390/ma11122468.Mwangi J, Hao X, Lai R, et al. Antimicrobial peptides: new hope in the war against multidrug resistance. Zool Res. 2019; 40(6):488–505. DOI: 10.24272/j.issn.2095-8137.2019.062.Shahrour H, Ferrer-Espada R, Dandache I, et al. AMPs as Anti-biofilm Agents for Human Therapy and Prophylaxis. Adv Exp Med Biol. 2019; 1117:257–279. DOI: 10.1007/978-981-13-3588-4_14.Pletzer D, Hancock RE. Antibiofilm Peptides: Potential as Broad-Spectrum Agents. J Bacteriol. 2016; 198(19):2572–2578. DOI: 10.1128/JB.00017-16.Piotrowska U, Sobczak M, Oledzka E. Current state of a dual behaviour of antimicrobial peptides-Therapeutic agents and promising delivery vectors. Chem Biol Drug Des. 2017; 90(6):1079–1093. DOI: 10.1111/cbdd.13031.Yasir M, Willcox MDP, Dutta D. Action of Antimicrobial Peptides against Bacterial Biofilms. Materials (Basel). 2018; 11(12):2468. DOI: 10.3390/ma11122468.Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 2016; 6:194. DOI: 10.3389/fcimb.2016.00194.Shahrour H, Ferrer-Espada R, Dandache I, et al. AMPs as Anti-biofilm Agents for Human Therapy and Prophylaxis. Adv Exp Med Biol. 2019; 1117:257–279. DOI: 10.1007/978-981-13-3588-4_14.Borrelli A, Tornesello AL, Tornesello ML, et al. Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents. Molecules. 2018; 23(2):295. DOI: 10.3390/molecules23020295.Piotrowska U, Sobczak M, Oledzka E. Current state of a dual behaviour of antimicrobial peptides-Therapeutic agents and promising delivery vectors. Chem Biol Drug Des. 2017; 90(6):1079–1093. DOI: 10.1111/cbdd.13031.Yu G, Baeder DY, Regoes RR, et al. Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics. Proc Biol Sci. 2018; 285(1874):20172687. DOI: 10.1098/rspb.2017.2687.Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 2016; 6:194. DOI: 10.3389/fcimb.2016.00194.Midura-Nowaczek K, Markowska A. Antimicrobial peptides and their analogs: searching for new potential therapeutics. Perspect. Medicin. Chem. 2014; 6:73–80. DOI: 10.4137/PMC.S13215.Borrelli A, Tornesello AL, Tornesello ML, et al. Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents. Molecules. 2018; 23(2):295. DOI: 10.3390/molecules23020295.Koo HB, Seo J. Antimicrobial peptides under clinical investigation. Pept. Sci. 2019; 111:e24122. DOI: 10.1002/pep2.24122.Yu G, Baeder DY, Regoes RR, et al. Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics. Proc Biol Sci. 2018; 285(1874):20172687. DOI: 10.1098/rspb.2017.2687.Rubinchik E, Dugourd D, Algara T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009; 34(5):457–461. DOI: 10.1016/j.ijantimicag.2009.05.003.Midura-Nowaczek K, Markowska A. Antimicrobial peptides and their analogs: searching for new potential therapeutics. Perspect. Medicin. Chem. 2014; 6:73–80. DOI: 10.4137/PMC.S13215.Ming L, Huang JA. The Antibacterial Effects of Antimicrobial Peptides OP-145 against Clinically Isolated Multi-Resistant Strains. Jpn J Infect Dis. 2017; 70(6):601–603. DOI: 10.7883/yoken.JJID.2017.090.Koo HB, Seo J. Antimicrobial peptides under clinical investigation. Pept. Sci. 2019; 111:e24122. DOI: 10.1002/pep2.24122.Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013; 66(10):571–591. DOI: 10.1038/ja.2013.86.Rubinchik E, Dugourd D, Algara T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009; 34(5):457–461. DOI: 10.1016/j.ijantimicag.2009.05.003.Ma JK, Drake PM, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet. 2003; 4(10):794–805. DOI: 10.1038/nrg1177.Ming L, Huang JA. The Antibacterial Effects of Antimicrobial Peptides OP-145 against Clinically Isolated Multi-Resistant Strains. Jpn J Infect Dis. 2017; 70(6):601–603. DOI: 10.7883/yoken.JJID.2017.090.Chernysh S, Kim SI, Bekker G, et al. Antiviral and antitumor peptides from insects. Proc Natl Acad Sci U S A. 2002; 99(20):12628–12632. DOI: 10.1073/pnas.192301899.Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013; 66(10):571–591. DOI: 10.1038/ja.2013.86.Chernysh SI. Insects defend themselves: molecules and cells of the immune response. St. Petersburg University: Journal. 2000; 20(3543):11–12. In RussianMa JK, Drake PM, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet. 2003; 4(10):794–805. DOI: 10.1038/nrg1177.[Черныш С.И. Насекомые защищаются: молекулы и клетки иммунного ответа. Санкт-Петербургский университет : Журнал. 2000; 20(3543):11–12].Chernysh S, Kim SI, Bekker G, et al. Antiviral and antitumor peptides from insects. Proc Natl Acad Sci U S A. 2002; 99(20):12628–12632. DOI: 10.1073/pnas.192301899.Xiong YQ, Hady WA, Deslandes A, et al. Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(11):5325–5330. DOI: 10.1128/AAC.00453-11.Chernysh SI. Insects defend themselves: molecules and cells of the immune response. St. Petersburg University: Journal. 2000; 20(3543):11–12. In RussianBreidenstein EB, Courvalin P, Meziane-Cherif D. Antimicrobial Activity of Plectasin NZ2114 in Combination with Cell Wall Targeting Antibiotics Against VanA-Type Enterococcus faecalis. Microb Drug Resist. 2015; 21(4):373–379. DOI: 10.1089/mdr.2014.0221.Xiong YQ, Hady WA, Deslandes A, et al. Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(11):5325–5330. DOI: 10.1128/AAC.00453-11.Zheng X, Wang X, Teng D, et al. Mode of action of plectasin-derived peptides against gas gangrene-associated Clostridium perfringens type A. PLoS One. 2017; 12(9):e0185215. DOI: 10.1371/journal.pone.0185215.Breidenstein EB, Courvalin P, Meziane-Cherif D. Antimicrobial Activity of Plectasin NZ2114 in Combination with Cell Wall Targeting Antibiotics Against VanA-Type Enterococcus faecalis. Microb Drug Resist. 2015; 21(4):373–379. DOI: 10.1089/mdr.2014.0221.Ostorhazi E, Holub MC, Rozgonyi F, et al. Broad-spectrum antimicrobial efficacy of peptide A3- APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int J Antimicrob Agents. 2011; 37(5):480–484. DOI: 10.1016/j.ijantimicag.2011.01.003.Zheng X, Wang X, Teng D, et al. Mode of action of plectasin-derived peptides against gas gangrene-associated Clostridium perfringens type A. PLoS One. 2017; 12(9):e0185215. DOI: 10.1371/journal.pone.0185215.Ostorhazi E, Horvath A, Szabo D, et al. Transdermally administered proline-arginine-rich host defense peptides show systemic efficacy in a lethal mouse bacteremia model. Amino Acids. 2017; 49(9):1647–1651. DOI: 10.1007/s00726-017-2457-7.Ostorhazi E, Holub MC, Rozgonyi F, et al. Broad-spectrum antimicrobial efficacy of peptide A3- APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int J Antimicrob Agents. 2011; 37(5):480–484. DOI: 10.1016/j.ijantimicag.2011.01.003.Ostorhazi E, Voros E, Nemes-Nikodem E, et al. Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2013; 42(6):537–543. DOI: 10.1016/j.ijantimicag.2013.08.001.Ostorhazi E, Horvath A, Szabo D, et al. Transdermally administered proline-arginine-rich host defense peptides show systemic efficacy in a lethal mouse bacteremia model. Amino Acids. 2017; 49(9):1647–1651. DOI: 10.1007/s00726-017-2457-7.Riool M, de Breij A, Drijfhout JW, et al. Antimicrobial Peptides in Biomedical Device Manufacturing. Front Chem. 2017; 5:63. DOI: 10.3389/fchem.2017.00063.Ostorhazi E, Voros E, Nemes-Nikodem E, et al. Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2013; 42(6):537–543. DOI: 10.1016/j.ijantimicag.2013.08.001.Yu K, Alzahrani A, Khoddami S, et al. Rapid Assembly of Infection-Resistant Coatings: Screening and Identification of Antimicrobial Peptides Works in Cooperation with an Antifouling Background. ACS Appl Mater Interfaces. 2021; 13(31):36784–36799. DOI: 10.1021/acsami.1c07515.Riool M, de Breij A, Drijfhout JW, et al. Antimicrobial Peptides in Biomedical Device Manufacturing. Front Chem. 2017; 5:63. DOI: 10.3389/fchem.2017.00063.Shahid A, Aslam B, Muzammil S, et al. The prospects of antimicrobial coated medical implants. J Appl Biomater Funct Mater. 2021; 19:22808000211040304. DOI: 10.1177/22808000211040304.Yu K, Alzahrani A, Khoddami S, et al. Rapid Assembly of Infection-Resistant Coatings: Screening and Identification of Antimicrobial Peptides Works in Cooperation with an Antifouling Background. ACS Appl Mater Interfaces. 2021; 13(31):36784–36799. DOI: 10.1021/acsami.1c07515.Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res. 2005; 30(7):505–515. DOI: 10.1080/02713680590968637.Shahid A, Aslam B, Muzammil S, et al. The prospects of antimicrobial coated medical implants. J Appl Biomater Funct Mater. 2021; 19:22808000211040304. DOI: 10.1177/22808000211040304.Dijksteel GS, Ulrich MMW, Middelkoop E, et al. Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs). Front Microbiol. 2021; 12:616979. DOI: 10.3389/fmicb.2021.616979.Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res. 2005; 30(7):505–515. DOI: 10.1080/02713680590968637.Cassone M, Otvos L Jr. Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev Anti Infect Ther. 2010; 8(6):703–716. DOI: 10.1586/eri.10.38.Dijksteel GS, Ulrich MMW, Middelkoop E, et al. Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs). Front Microbiol. 2021; 12:616979. DOI: 10.3389/fmicb.2021.616979.Ruden S, Rieder A, Chis Ster I, et al. Synergy Pattern of Short Cationic Antimicrobial Peptides Against Multidrug-Resistant Pseudomonas aeruginosa. Front Microbiol. 2019; 10:2740. DOI: 10.3389/fmicb.2019.02740.Cassone M, Otvos L Jr. Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev Anti Infect Ther. 2010; 8(6):703–716. DOI: 10.1586/eri.10.38.Duong L., Gross S.P., Siryaporn A. Developing Antimicrobial Synergy With AMPs. Front. Med. Technol. 2021; 3:9. DOI: 10.3389/fmedt.2021.640981.Ruden S, Rieder A, Chis Ster I, et al. Synergy Pattern of Short Cationic Antimicrobial Peptides Against Multidrug-Resistant Pseudomonas aeruginosa. Front Microbiol. 2019; 10:2740. DOI: 10.3389/fmicb.2019.02740.Pollini S, Brunetti J, Sennati S, et al. Synergistic activity profile of an antimicrobial peptide against multidrug- resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. J Pept Sci. 2017; 23(4):329–333. DOI: 10.1002/psc.2978.Duong L., Gross S.P., Siryaporn A. Developing Antimicrobial Synergy With AMPs. Front. Med. Technol. 2021; 3:9. DOI: 10.3389/fmedt.2021.640981.Zharkova MS, Orlov DS, Golubeva OY, et al. Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics- A Novel Way to Combat Antibiotic Resistance? Front Cell Infect Microbiol. 2019; 9:128. DOI: 10.3389/fcimb.2019.00128.Pollini S, Brunetti J, Sennati S, et al. Synergistic activity profile of an antimicrobial peptide against multidrug- resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. J Pept Sci. 2017; 23(4):329–333. DOI: 10.1002/psc.2978.Kopeikin PM, Zharkova MS, Kolobov AA, et al. Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs. Front Cell Infect Microbiol. 2020; 10:552905. DOI: 10.3389/fcimb.2020.552905.Zharkova MS, Orlov DS, Golubeva OY, et al. Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics- A Novel Way to Combat Antibiotic Resistance? Front Cell Infect Microbiol. 2019; 9:128. DOI: 10.3389/fcimb.2019.00128.Kopeikin PM, Zharkova MS, Kolobov AA, et al. Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs. Front Cell Infect Microbiol. 2020; 10:552905. DOI: 10.3389/fcimb.2020.552905.Kopeikin PM, Zharkova MS, Kolobov AA, et al. Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs. Front Cell Infect Microbiol. 2020; 10:552905. DOI: 10.3389/fcimb.2020.552905.

The authors declare that there are no conflicts of interest present.